FINNFOREL-OY
9.11.2021 10:27:08 CET | Business Wire | Press release
Finnish technology company Finnforel has become one of the world's leading ecological fish farms since it was founded in 2017. The company’s products are currently sold in more than a thousand grocery stores in Finland under the Saimaan Tuore brand. Finnforel achieved a significant breakthrough in November 2020, when its million-kilo production plant in Varkaus achieved maximum capacity level for premium fish farming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005798/en/
With the investment programme announced today, Finnforel enters its next growth phase, as the company aims for rapid expansion in both the Finnish and global markets.
“Only 0.1 percent of all the fish in the world is produced in an ecologically sustainable way. This is a massive EUR 300 billion business that must change if we want to save our seas and lakes. I believe that Finnforel’s highly refined model, which works without antibiotics or environmental emissions, can claim a significant part of this market. Over the next decade, the mission of the Finnforel team is to bring Finnish genetics and fish farming know-how to the world. In the future, fish will be farmed where consumers are,” says Pekka Viljakainen, Chairman of the Board and one of the founders of Finnforel Oy.
Finnforel is further expanding the production capacity of its Varkaus plant from one million to three million kilos. The resulting “Finnforel Gigafactor” concept will cover the entire fish farming process, from juvenile fish to ready consumer products. Construction work on the extension, which will cost approximately EUR 25 million, will begin immediately. In December 2021, Finnforel will begin exporting its fish products to the United Kingdom, Germany and the Netherlands. At the same time, the company is entering the design phase for several similar gigafactor projects in Europe, Russia and the Middle East.
Finland’s first selective breeding centre for rainbow trout to be built in Hollola
A significant part of Finnforel’s expansion plans is to introduce to Finland industrial-scale broodstock and fry production suitable for Recirculating Aquaculture Systems. At present, most of the eggs used in fish farming in Finland are imported. Finnforel is building a EUR 12 million genetics and fry plant in Hollola that, upon completion, will have the capacity to produce eggs for six Finnforel gigafactor plants around the world.
The project, which is being implemented in close co-operation with Natural Resources Institute Finland, is also important in terms of Finland's emergency supply. Together with the Finnish institute, Finnforel will help secure the supply of fish eggs and fry, for example in crisis situations. Since the early 1990s, Natural Resources Institute Finland has carried out pioneering research in rainbow trout genetics, breeding and animal health. This project marks the first time that the results of this work are being applied and commercialised to this extent.
“According to the business model created by Finnforel, fish will be processed from eggs to consumer packaging. By securing the entire production chain, we create an easy way for consumers and retailers to buy and sell fresh and delicious fish. The consumption of fish is growing internationally, and I firmly believe that more vigilant consumers will increasingly favour organically produced alternatives that are easy and quick to prepare,” says Max Alfthan, Managing Director of Finnforel.
Significant new owners
Finnforel is financing these investments totalling EUR 45 million through a EUR 34 million share issue, EUR 4.5 million from the European Maritime and Fisheries Fund (EMFF) and EUR 6 million in loans from banks.
The share issue will make significant Finnish and international institutional investors shareholders in Finnforel. These include Ahlström Invest, Finnish Industry Investment Ltd (TESI), the European Investment Bank (European Fund for Strategic Investment), The Good Investors (Ireland/France) and other European family enterprises.
Finnforel’s press conference was held on Tuesday 9th of November from 11.00 am onwards. The recording of the press conference can be viewed here: https://www.finnforel.com/
Read more about Finnforel here: https://www.finnforel.com/
For more information: https://youtu.be/e6Q8LbLddXw
Finnforel Oy is a Recirculating Aquaculture Systems (RAS) facility and Finnish family business specialising in genetics and related technology that was founded in 2017. The company currently has pilot plants in Varkaus, Hollola and Joroinen that produce approximately one million kilos of organically farmed rainbow trout each year. The company's best-known brand is Saimaan Tuore, whose rainbow trout products are available in more than a thousand grocery stores throughout Finland.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005798/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
